EUVIMEDEUVIMED entdecken
Crossref

Glymphatic Dysfunction in Non‐Manifesting Carriers of LRRK2 and GBA Pathogenic Variants

Dongling Zhang iD, Ling Luo, Lingyu Li, Junye Yao, Qianyi Zheng, Hongjian He, Tao Feng iD, Xi-Jian Dai iD, Tao Wu

Movement Disorders · 2025

DOI: 10.1002/mds.30306 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, 2025. Verfasst von Dongling Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Bei…. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Parkinson Disease, Glucosylceramidase, Glymphatic System. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Beijing Natural Science Foundation, National Natural Science Foundation of China, Outstanding Youth Science Fund of Jiangxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non‐manifesting carriers of LRRK2 and GBA pathogenic variants represent a unique cohort for investigating neuroprotective interventions at the prodromal stage of Parkinson's disease (PD). A critical challenge is identifying effective markers to predict non‐manifesting carriers at high risk of developing PD.

Objectives

Our goal was to investigate whether glymphatic function is impaired in non‐manifesting carriers and to evaluate the potential of glymphatic dysfunction as a marker for identifying individuals at high risk of PD.

Methods

We used diffusion‐tensor imaging analysis along the perivascular space (ALPS) method to assess glymphatic function in participants from the Parkinson's Progression Markers Initiative (PPMI) dataset. Cross‐sectional and longitudinal changes in the ALPS index were evaluated, and baseline predictors of clinical progression were identified. The association between ALPS index and the risk of phenoconversion was examined using Kaplan–Meier survival analysis and Cox proportional hazards regression.

Results

Eighty non‐manifesting carriers of LRRK2 and GBA pathogenic variants were included. ALPS index values were reduced cross‐sectionally and longitudinally, and were correlated with cognitive function and daytime sleepiness scores. Baseline ALPS index values predicted a decline in Hopkins Verbal Learning Test‐immediate recall scores over a 3‐year follow‐up period. During follow‐up, 17 non‐manifesting carriers converted to clinically defined PD. Increasing ALPS index values were associated with a decreased risk of phenoconversion (hazard ratio [95% confidence interval] = 0.128 [0.029–0.565], P = 0.0013).

Conclusions

Glymphatic function is impaired in non‐manifesting carriers. Glymphatic dysfunction is associated with an increased risk of phenoconversion. The ALPS index has the potential as a marker for identifying individuals at high risk of developing PD. © 2025 International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2Parkinson DiseaseGlucosylceramidaseGlymphatic SystemHumansMaleFemaleMiddle AgedAgedCross-Sectional StudiesDiffusion Tensor ImagingDisease ProgressionHeterozygoteLongitudinal StudiesProdromal Symptoms

Stichwörter der Autor:innen

Parkinson's diseaseanalysis along the perivascular spaceglymphatic functionnon‐manifesting carriers of LRRK2 and GBA pathogenic variantsphenoconversionprodromal stage

Substanzen

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanGlucosylceramidaseGBA protein, human

Autor:innen und Institutionen

  • Department of Neurology, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Center for Movement Disorders, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Polytechnic Institute, Zhejiang University, Zhejiang, China.
  • Clinical and Technical Support, Philips Healthcare, Shanghai, China.
  • School of Physics, Zhejiang University, Zhejiang, China.
  • Jiangxi Provincial Key Laboratory of Intelligent Medical Imaging, Nanchang, China.

ORCID-Profile: Dongling Zhang, Tao Feng, Xi-Jian Dai

Förderung

  • Beijing Natural Science Foundation
  • National Natural Science Foundation of China
  • Outstanding Youth Science Fund of Jiangxi Province
  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Zhang, D., Luo, L., Li, L., Yao, J., Zheng, Q., He, H., Feng, T., Dai, X. J., & Wu, T. (2025). Glymphatic Dysfunction in Non‐Manifesting Carriers of LRRK2 and GBA Pathogenic Variants. Movement Disorders. https://doi.org/10.1002/mds.30306

Vancouver

Zhang D, Luo L, Li L, Yao J, Zheng Q, He H, et al. Glymphatic Dysfunction in Non‐Manifesting Carriers of LRRK2 and GBA Pathogenic Variants. Movement Disorders. 2025. doi:10.1002/mds.30306

BibTeX
@article{Zhang2025,
  author = {Zhang, Dongling and Luo, Ling and Li, Lingyu and Yao, Junye and Zheng, Qianyi and He, Hongjian and Feng, Tao and Dai, Xi-Jian and Wu, Tao},
  title = {Glymphatic Dysfunction in Non‐Manifesting Carriers of LRRK2 and GBA Pathogenic Variants},
  journal = {Movement Disorders},
  year = {2025},
  doi = {10.1002/mds.30306}
}
Kostenlos starten →